Karolinska Development

Regulatory Filings • Oct 3, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

STOCKHOLM, SWEDEN – October 3, 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) (“Karolinska Development” or the “Company”) announces that its portfolio company Aprea Therapeutics, Inc. (“Aprea”) has announced the pricing of its initial public offering of 5,666,667 shares of its common stock at a price to the public of USD 15 per share. Based on the price to the public per share, the net profit effect due to changed valuation of Karolinska Development’s holding in Aprea amounts to approx. SEK 58 million.

Trading of shares in Aprea is expected to commence October 3, 2019 on Nasdaq Global Select Market, under the symbol “APRE.” The offering is expected to close on October 7, 2019, subject to the satisfaction of customary closing conditions. Karolinska Development has signed a customary lock up agreement, preventing a sale of the shares it holds in Aprea during a 180 days period calculated from the end of the offer period.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. Aprea’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

A registration statement relating to Aprea common stock has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on October 2, 2019. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

**About Karolinska Development AB

**Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 06.30 CET on 3 October 2019.

Attachment

• KD PR Aprea 2019-10-03 ENG